You just read:

New analyses show Novartis' Entresto™ reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction (HFrEF) regardless of prior heart failure hospital admissions or background therapy

News provided by

Novartis Pharmaceuticals Corporation

Apr 02, 2016, 11:03 ET